Alessia C.
- Country
- Italy
- Department
- Hematology
Research Overview
- Evaluation of Emavusertib and Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma: A Dose Escalation and Expansion Study
- Efficacy of Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma Post-CAR T-Cell Therapy
- Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of Ibrutinib and Rituximab in Treatment-naïve Follicular Lymphoma Patients
Data & Insights
Has run more than one trial at 6 of 70 partner sites.
Specializations
Lymphoma Treatment Innovation
This investigator specializes in advancing treatment approaches for follicular lymphoma, with particular focus on combination therapies involving targeted agents and immunotherapy.
- Early-stage lymphoma management
- Immunotherapy combinations
- Radiation therapy optimization
The research explores novel therapeutic combinations including rituximab and obinutuzumab-based treatments.
Advanced B-Cell Lymphomas
Expertise in treating aggressive B-cell lymphomas, including innovative approaches for diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma.
- CAR T-cell therapy resistance
- Novel antibody therapeutics
- Refractory disease management
Focus includes developing treatment strategies for patients who have progressed after CAR T-cell therapy.
CNS Lymphoma Research
Specialized research in primary central nervous system lymphoma (PCNSL), investigating novel therapeutic approaches and drug combinations.
- Targeted therapy development
- Combination treatment strategies
- Hematologic malignancy management
Investigation of innovative compounds including emavusertib and its combinations for resistant disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.